JUBILANT PHARMOVA LTD (JUBLPHARMA) financials

JUBILANT PHARMOVA LTD (JUBLPHARMA) NSE/BSE financials on Fincrux: quarterly results, profit and loss, cash flow, balance sheet, ratios, and shareholding.

Jubilant Pharmova Ltd is an integrated global pharmaceuticals company having three business segments i.e. pharmaceuticals, contract research and development services and proprietary novel drugs.[1]

Market Cap: ₹14,952Cr.
Current Price: ₹939
Stock P/E: 473
ROE: 3.06%
ROCE: 1.80%
Book Value: ₹145
Dividend Yield: 0.53%
52W High / Low: ₹1,185/784

In Jun 2026, JUBILANT PHARMOVA LTD (JUBLPHARMA) reported sales ₹67.10 Cr and net profit ₹7.30 Cr.

Annual TTM: sales ₹271 Cr, net profit ₹65 Cr.

Shareholding: Promoters 47.67% (Jun 2026), FIIs 15.87% (Jun 2026), DIIs 12.40% (Jun 2026), Public 23.50% (Jun 2026), Others 0.55% (Jun 2026).

JUBLPHARMA quarterly results (₹ Cr.)
Category	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	61.40	56.10	60.70	59.50	66.40	67.30	70.30	67.10
Expenses	51.40	46.10	49.80	49.20	54.60	55.10	55.80	55.10
Operating Profit	10.00	10.00	10.90	10.30	11.80	12.20	14.50	12.00
OPM %	16.29%	17.83%	17.96%	17.31%	17.77%	18.13%	20.63%	17.88%
Other Income	15.70	2.80	13.00	2.40	42.40	0.40	-8.20	0.10
Interest	3.20	3.30	3.10	3.00	2.50	0.90	0.90	0.90
Depreciation	1.70	1.50	1.50	1.50	1.60	1.60	1.30	1.40
Profit before tax	20.80	8.00	19.30	8.20	50.10	10.10	4.10	9.80
Tax %	49.52%	33.75%	29.53%	29.27%	112.77%	34.65%	-1,295.12%	25.51%
Net Profit	10.50	5.30	13.60	5.80	-6.40	6.60	57.20	7.30
EPS in Rs	0.66	0.33	0.85	0.36	-0.40	0.41	3.59	0.46
Raw PDF	—	—	—	—	—	—	—	—

JUBLPHARMA profit and loss (₹ Cr.)
Category	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	3,140	2,710	726	810	785	231	264	271
Expenses	2,765	2,282	719	807	767	191	215	221
Operating Profit	375	427	6	3	18	41	49	50
OPM %	12%	16%	0.9%	0.4%	2.2%	18%	19%	19%
Other Income	168	48	126	138	102	17	37	35
Interest	136	102	11	18	30	13	7	5
Depreciation	107	100	37	43	48	7	6	6
Profit before tax	299	273	85	79	42	38	72	74
Tax %	-7%	21%	5%	37%	24%	50%	13%	—
Net Profit	321	214	80	50	32	19	63	65
EPS in Rs	20.16	13.46	5.05	3.13	1.98	1.21	3.97	4.06
Dividend Payout %	25%	37%	99%	159%	252%	414%	126%	—

JUBLPHARMA balance sheet (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	16	16	16	16	16	16	16	16
Reserves	2,324	2,591	1,267	2,423	2,399	2,359	2,302	2,296
Borrowings	1,702	2,013	504	183	346	380	336	53
Other Liabilities	821	814	58	274	248	237	255	68
Total Liabilities	4,864	5,433	1,845	2,896	3,008	2,992	2,910	2,433
Fixed Assets	1,491	1,865	127	637	687	711	699	116
CWIP	284	59	0	35	47	37	19	12
Investments	1,764	1,764	1,646	1,646	1,657	1,657	1,657	2,176
Other Assets	1,325	1,746	71	578	617	587	535	129
Total Assets	4,864	5,433	1,845	2,896	3,008	2,992	2,910	2,433

JUBLPHARMA cash flows (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operating Activity	182	317	608	-4	-65	143	136	94
Cash from Investing Activity	-285	-198	178	93	31	-40	-2	34
Cash from Financing Activity	85	-41	-782	-107	22	-78	-157	-130
Net Cash Flow	-18	78	5	-18	-12	25	-24	-2
Free Cash Flow	-99	120	516	-41	-124	76	115	74
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit	71%	90%	152%	245%	-1,539%	888%	364%	204%

JUBLPHARMA shareholding pattern (%)
Category	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Promoters	50.67%	50.67%	50.67%	47.67%	47.67%	47.67%	47.67%	47.67%
FIIs	17.94%	16.96%	17.23%	17.40%	16.56%	15.96%	15.90%	15.87%
DIIs	5.66%	6.99%	7.05%	9.52%	10.53%	11.23%	11.63%	12.40%
Public	25.17%	24.82%	24.48%	24.83%	24.60%	24.57%	24.25%	23.50%
Others	0.56%	0.56%	0.56%	0.56%	0.63%	0.57%	0.56%	0.55%
No. of Shareholders	89,456	1,02,442	96,526	99,673	93,336	90,133	86,347	82,703

JUBLPHARMA key ratios
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	51	49	0	66	85	90	325	33
Inventory Days	87	142	0	355	276	258	—	—
Days Payable	106	134	—	174	145	152	—	—
Cash Conversion Cycle	32	58	0	247	216	196	325	33
Working Capital Days	-5	85	-13	126	93	88	254	-22
ROCE %	8%	10%	12%	4%	4%	3%	2%	2%

JUBLPHARMAUpdated 17 Oct 2026, 21:33

Jubilant Pharmova Ltd

JUBLPHARMAUpdated 17 Oct 2026, 21:33

Market Cap

₹14,952Cr.

Current Price

₹939

High / Low

₹1,185/784

Stock P/E

473

ROE3.06%

ROCE1.80%

Book Value₹145

Face Value₹1.00

Dividend Yield0.53%

About

Jubilant Pharmova Ltd is an integrated global pharmaceuticals company having three business segments i.e. pharmaceuticals, contract research and development services and proprietary novel drugs.[1]

Quarterly results

Last reported quarters₹ Cr.

Quarter	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Jun 2023	217.4	6.4	213.2	15.9	11.4	2.3	17.39	1.9	0.12
Sep 2023	186.3	7.1	185.5	18.4	11.9	0.2	300	-0.4	-0.03
Dec 2023	175.2	8.3	175.9	19	12.3	-2.3	4.35	-2.4	-0.15
Mar 2024	205.8	8.1	193.6	50.1	12.7	41.5	21.69	32.5	2.04
Jun 2024	53.2	3.3	43.4	-14.3	1.9	-9.7	5.15	-10.2	-0.64
Sep 2024	61.4	3.2	51.4	15.7	1.7	20.8	49.52	10.5	0.66
Dec 2024	56.1	3.3	46.1	2.8	1.5	8	33.75	5.3	0.33
Mar 2025	60.7	3.1	49.8	13	1.5	19.3	29.53	13.6	0.85
Jun 2025	59.5	3	49.2	2.4	1.5	8.2	29.27	5.8	0.36
Sep 2025	66.4	2.5	54.6	42.4	1.6	50.1	112.77	-6.4	-0.4
Dec 2025	67.3	0.9	55.1	0.4	1.6	10.1	34.65	6.6	0.41
Mar 2026	70.3	0.9	55.8	-8.2	1.3	4.1	-1295.12	57.2	3.59
Jun 2026	67.1	0.9	55.1	0.1	1.4	9.8	25.51	7.3	0.46

Profit & loss

Annual statement₹ Cr.

Year	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Mar 2015	3172	233	2890	305	107	246	17	205	12.88
Mar 2016	2656	201	2344	62	87	86	16	73	4.58
Mar 2017	2491	174	2173	52	81	115	31	79	4.97
Mar 2018	3306	135	2765	45	83	368	28	263	16.54
Mar 2019	3439	129	3112	72	86	183	20	148	9.27
Mar 2020	3140	136	2765	168	107	299	-7	321	20.16
Mar 2021	2710	102	2282	48	100	273	21	214	13.46
Mar 2022	726	11	719	126	37	85	5	80	5.05
Mar 2023	810	18	807	138	43	79	37	50	3.13
Mar 2024	785	30	767	102	48	42	24	32	1.98
Mar 2025	231	13	191	17	7	38	50	19	1.21
Mar 2026	264	7	215	37	6	72	13	63	3.97
TTM	271	5	221	35	6	74	—	65	4.06

Shareholding pattern

As of Jun 2026%

Holder	Share
Promoters	47.67%
FIIs	15.87%
DIIs	12.4%
Public	23.5%
Others	0.55%

Shareholding trend

Ownership over time%

Quarter	Promoters	FIIs	DIIs	Government	Public	Others
Sep 2023	50.67%	23.2%	1.64%	—	23.89%	0.59%
Dec 2023	50.67%	20.29%	2.89%	—	25.56%	0.58%
Mar 2024	50.67%	19.06%	3.77%	—	25.91%	0.58%
Jun 2024	50.67%	19.5%	4.06%	—	25.18%	0.58%
Sep 2024	50.67%	17.94%	5.66%	—	25.17%	0.56%
Dec 2024	50.67%	16.96%	6.99%	—	24.82%	0.56%
Mar 2025	50.67%	17.23%	7.05%	—	24.48%	0.56%
Jun 2025	47.67%	17.4%	9.52%	—	24.83%	0.56%
Sep 2025	47.67%	16.56%	10.53%	—	24.6%	0.63%
Dec 2025	47.67%	15.96%	11.23%	—	24.57%	0.57%
Mar 2026	47.67%	15.9%	11.63%	—	24.25%	0.56%
Jun 2026	47.67%	15.87%	12.4%	—	23.5%	0.55%

Balance sheet

Assets & liabilities₹ Cr.

Period	Equity Capital	Reserves	Borrowings	Other Liabilities	Total Liabilities	Fixed Assets	CWIP	Investments	Other Assets	Total Assets
Mar 2015	16	1929	2279	963	5188	1446	20	1766	1955	5188
Mar 2016	16	1998	1808	507	4329	1415	36	1709	1169	4329
Mar 2017	16	2027	1698	651	4391	1421	65	1710	1195	4391
Mar 2018	16	2233	1424	951	4625	1438	115	1706	1365	4625
Mar 2019	16	2324	1702	821	4864	1491	284	1764	1325	4864
Mar 2020	16	2591	2013	814	5433	1865	59	1764	1746	5433
Mar 2021	16	1267	504	58	1845	127	0	1646	71	1845
Mar 2022	16	2423	183	274	2896	637	35	1646	578	2896
Mar 2023	16	2399	346	248	3008	687	47	1657	617	3008
Mar 2024	16	2359	380	237	2992	711	37	1657	587	2992
Mar 2025	16	2302	336	255	2910	699	19	1657	535	2910
Mar 2026	16	2296	53	68	2433	116	12	2176	129	2433

Cash flows

Operating, investing & financing₹ Cr.

Period	Operating	Investing	Financing	Net cash flow
Mar 2015	286	1319	-1647	-42
Mar 2016	164	522	-784	-98
Mar 2017	419	-43	-338	38
Mar 2018	558	-127	-470	-40
Mar 2019	182	-285	85	-18
Mar 2020	317	-198	-41	78
Mar 2021	608	178	-782	5
Mar 2022	-4	93	-107	-18
Mar 2023	-65	31	22	-12
Mar 2024	143	-40	-78	25
Mar 2025	136	-2	-157	-24
Mar 2026	94	34	-130	-2

Key ratios

Historical financial ratios

Category	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	37	47	57	54	51	49	0	66	85	90	325	33
Inventory Days	97	119	127	120	87	142	0	355	276	258	—	—
Days Payable	96	91	136	154	106	134	—	174	145	152	—	—
Cash Conversion Cycle	38	75	47	21	32	58	0	247	216	196	325	33
Working Capital Days	24	-19	22	6	-5	85	-13	126	93	88	254	-22
ROCE %	6%	7%	7%	14%	8%	10%	12%	4%	4%	3%	2%	2%

Frequently asked questions

Quick answers about this company's financials on Fincrux

What is the market cap of JUBILANT PHARMOVA LTD (JUBLPHARMA)?

The reported market capitalisation for JUBILANT PHARMOVA LTD (JUBLPHARMA) is ₹14,952Cr. on Fincrux. Figures may update with market data and filings.

What is the current share price of JUBLPHARMA?

The current price shown for JUBILANT PHARMOVA LTD (JUBLPHARMA) on Fincrux is ₹939 with a 52-week high/low of ₹1,185/784.

What is the P/E ratio of JUBILANT PHARMOVA LTD (JUBLPHARMA)?

The stock P/E for JUBILANT PHARMOVA LTD (JUBLPHARMA) is 473 on Fincrux, with ROE at 3.06% and ROCE at 1.80%.

What were JUBLPHARMA latest quarterly results?

For Jun 2026, JUBILANT PHARMOVA LTD (JUBLPHARMA) reported sales ₹67.10 Cr and net profit ₹7.30 Cr (figures in ₹ crore unless noted).

What are JUBLPHARMA annual sales and net profit?

For TTM, JUBILANT PHARMOVA LTD (JUBLPHARMA) shows sales of ₹271 Cr and net profit of ₹65 Cr on the Fincrux profit & loss statement.

Who owns JUBILANT PHARMOVA LTD (JUBLPHARMA)?

Latest shareholding for JUBILANT PHARMOVA LTD (JUBLPHARMA) on Fincrux: Promoters 47.67% (Jun 2026), FIIs 15.87% (Jun 2026), DIIs 12.40% (Jun 2026), Public 23.50% (Jun 2026), Others 0.55% (Jun 2026).

Where can I find JUBILANT PHARMOVA LTD (JUBLPHARMA) financials?

JUBILANT PHARMOVA LTD (JUBLPHARMA) financials on Fincrux include quarterly results, profit and loss, cash flow, balance sheet, key ratios, and shareholding patterns for NSE/BSE research.

Does Fincrux show JUBLPHARMA balance sheet and cash flow?

Yes. The JUBILANT PHARMOVA LTD (JUBLPHARMA) page on Fincrux includes balance sheet, cash flow statements, historical ratios, and ownership trends alongside quarterly and annual results.

Figures in ₹ crore unless noted. Data sourced for research and may lag filings.

Last updated 17 October 2026 at 21:33